ArticleFrontiers in psychiatry2025
Exploring the relationship and shared mechanisms of major depressive disorder and diabetic kidney disease: a comprehensive clinical and genetic analysis.
Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Major depressive disorder (MDD) is a common comorbidity in diabetes mellitus (DM), while diabetic kidney disease (DKD) represents a severe complication of DM. However, the clinical and genetic associations between MDD and DKD remain unclear. This study aimed to investigate their shared biomarkers, molecular pathways, and immune features. Methods: We analyzed data from the National Health and Nutrition Examination Survey (NHANES, 2005-2018) to assess the association between MDD and DKD. Genetic correlation was evaluated using linkage disequilibrium score regression (LDSC), and causality was tested with Mendelian randomization (MR). Gene expression datasets were integrated to identify crosstalk genes, followed by protein-protein interaction (PPI) analysis to detect hub genes. Diagnostic performance was validated using least absolute shrinkage and selection operator (LASSO) regression and receiver operating characteristic (ROC) curves. Immune infiltration was assessed, and potential therapeutic compounds were predicted through connectivity map (cMAP) analysis and molecular docking. Results: Clinical analysis revealed a significant association between MDD and DKD (OR = 1.45, 95% CI: 1.28-1.64). LDSC indicated a significant genetic correlation (r = 0.2153, P = 0.008), although MR analysis did not support a causal relationship. A total of 83 crosstalk genes were identified, primarily enriched in inflammation and immune regulation pathways. PPI analysis highlighted eight hub genes, with CD163 and KLRB1 emerging as promising shared diagnostic biomarkers. Validation using LASSO and ROC confirmed their diagnostic potential. Immune infiltration analysis revealed shared immune cell alterations. Furthermore, cMAP analysis and molecular docking suggested rucaparib and levocetirizine as candidate therapeutic agents. Discussion: Our findings demonstrate a genetic and immunological link between MDD and DKD. CD163 and KLRB1 may serve as potential biomarkers and therapeutic targets, offering new insights into the shared mechanisms and treatment strategies for comorbid MDD and DKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.